Skip to main content
UniHealth

Doctor search

Kendall Beck, MD

Gastroenterology · San Francisco

NPI 1972892057

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Office
1
Since medical school
15 years
Graduated 2011

Offices

1 location · Regents of the University of California · 706 clinicians in this group

Looking this up.

Hospitals listed: UCSF Health Stanyan Hospital · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beck’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A122880 · Current

Licensed to practise in California · since 2012 · expires 2028-08-31 · University of Texas Medical School at Houston.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Gastroenterology

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Health St. Mary'S HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 60% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Health St. Mary'S Hospital

Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Health St. Mary'S Hospital
Clostridium Difficile (C.Diff)Infections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.95 (0 to 1.99) · 413 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.96 (0.58 to 1.34)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths146.74 (92.54 to 200.93) · 30 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths7.4 · 35 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.8 · 51 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.6 · 220 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths9.3 · 165 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 102 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 1,363 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.24 (0.02 to 0.46) · 2,530 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.32 (0.12 to 0.53) · 2,519 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.02 (0.73 to 5.31) · 590 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.63 (0 to 3.35) · 238 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.07 (0.43 to 3.7) · 554 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths12.7 (4.19 to 21.21) · 259 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.67 (1.51 to 9.83) · 203 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.7 (0.19 to 3.2) · 168 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.21 (0 to 0.99) · 2,258 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.2 · 158 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.6 · 61 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.1 · 291 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.4 · 251 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits5.5 · 189 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.1 · 213 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (3.7 to 8.5) · 30 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12 (8.3 to 17.1) · 30 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.5 · 176 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.3 · 61 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.1 (9.6 to 17.8) · 192 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.5) · 113 casesNo differentJan 2024 – Dec 2024

What patients said (587 patients answered, 20% of those asked)

Patient survey stars by topic at UCSF Health St. Mary'S Hospital
Cleanliness3
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information4
Overall hospital rating2
Quietness1
Recommend hospital2
Share of patients giving the best answer at UCSF Health St. Mary'S Hospital
Room was "always" clean66%
Nurses "always" communicated well73%
Doctors "always" communicated well76%
Staff "always" explained60%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand71%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)58%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand70%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect78%
"Always" quiet at night41%
"YES", patients would definitely recommend the hospital60%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$70,866

Medicare paid this office $70,866 for 323 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Removal of polyps or growths of large bowel using an endoscope with mechanical snare101$23,009$228
Long return visit (40+ min)71$13,046$120
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope66$5,588$85
Biopsy of large bowel using a flexible endoscope51$5,254$103
New patient visit (60+ min)20$3,318$166
See all 12 services
Every Original Medicare service billed
Removal of polyps or growths of large bowel using an endoscope with mechanical snare101$23,009$228
Long return visit (40+ min)71$13,046$120
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope66$5,588$85
Biopsy of large bowel using a flexible endoscope51$5,254$103
New patient visit (60+ min)20$3,318$166
Colorectal cancer screening; colonoscopy on individual at high risk15$2,851$190
Return visit (30+ min)27$2,284$85
New patient visit (45+ min)19$1,968$104
Diagnostic exam of large bowel using a flexible endoscope13$1,846$142
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's78$1,616$15
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,218$94
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito85$409$5

Procedures Medicare counted

Procedure volume Medicare published
Colonoscopy84More than 75% of doctors who do this
Upper gastrointestinal (GI) endoscopy for acid reflux73More than 70% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Removal of polyps or growths of large bowel using an endoscope with mechanical snare3147518085101
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope516853756866
Biopsy of large bowel using a flexible endoscope466723494651
Diagnostic exam of large bowel using a flexible endoscope2624–132013
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope–13–121513

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

323 Original Medicare patients in 2024. Average age 69 · Women 63% · Also on Medicaid 28% · Health risk score 1.65. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.

Conditions among them: High blood pressure 63% · Depression 26% · Diabetes 25% · Chronic kidney disease 23% · Cancer 22% · Coronary heart disease 19% · Atrial fibrillation 17% · Heart failure 15% · COPD 11% · Stroke 11% · Dementia 7%.

The office billed $946,844, Medicare allowed $89,521 and paid $70,866; for 715 services of 48 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024323715691.65$946,844$70,866
20233581,238711.95$990,784$78,003
2022312584711.69$935,070$62,789
2021231414691.73$599,924$44,722
2020335561681.89$903,697$67,670
2019273430681.87$664,096$54,793
2018353570691.81$860,815$67,958
2017146213691.81$315,937$26,727

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 13 services

Original Medicare services billed in 2023
Removal of polyps or growths of large bowel using an endoscope with mechanical snare84$18,987$223
Long return visit (40+ min)72$10,412$117
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope66$6,570$97
Biopsy of large bowel using a flexible endoscope45$4,964$108
New patient visit (60+ min)31$4,738$153
New patient visit (45+ min)34$3,505$103
Initial hospital care with moderate level of medical decision making at least 75 minutes17$2,816$156
Diagnostic exam of large bowel using a flexible endoscope20$2,766$138
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes19$2,223$117
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope15$1,388$93
Return visit (30+ min)13$1,060$82
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$857$71
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito84$398$5

2022: 17 services

Original Medicare services billed in 2022
Removal of polyps or growths of large bowel using an endoscope with mechanical snare48$10,241$213
Removal of polyps or growths of large bowel using an endoscope with mechanical snare32$6,996$219
Long return visit (40+ min)35$6,231$127
New patient visit (45+ min)36$4,041$112
New patient visit (60+ min)23$3,791$165
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope36$3,504$95
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope38$3,376$89
Biopsy of large bowel using a flexible endoscope29$2,885$99
Return visit (30+ min)24$1,891$79
Diagnostic exam of large bowel using a flexible endoscope13$1,865$143
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,675$120
Biopsy of large bowel using a flexible endoscope20$1,578$79
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$1,462$91
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope12$1,220$102
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$760$63
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito47$198$4
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito15$70$5

2021: 12 services

Original Medicare services billed in 2021
Removal of polyps or growths of large bowel using an endoscope with mechanical snare34$6,968$205
Removal of polyps or growths of large bowel using an endoscope with mechanical snare16$3,903$230
Long return visit (40+ min)21$3,462$128
Biopsy of large bowel using a flexible endoscope23$3,176$138
New patient visit (45+ min)28$2,990$107
New patient visit (60+ min)17$2,744$161
Initial hospital care with moderate level of medical decision making at least 75 minutes15$2,685$179
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope25$2,457$98
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope28$2,443$87
Return visit (30+ min)24$2,106$75
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$1,477$92
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito56$261$5

2020: 16 services

Original Medicare services billed in 2020
New patient visit (60+ min)54$7,267$135
Long return visit (40+ min)46$6,567$97
Biopsy of large bowel using a flexible endoscope42$5,463$130
Removal of polyps or growths of large bowel using an endoscope with mechanical snare24$5,367$224
Removal of polyps or growths of large bowel using an endoscope with mechanical snare23$5,277$229
Initial hospital care with moderate level of medical decision making at least 75 minutes25$4,535$181
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$3,743$94
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope37$3,376$91
Biopsy of large bowel using a flexible endoscope24$2,815$113
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope30$2,804$90
New patient visit (45+ min)18$1,975$110
Diagnostic exam of large bowel using a flexible endoscope13$1,882$145
Diagnostic exam of large bowel using a flexible endoscope11$1,869$170
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$1,800$64
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes12$1,481$123
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,235$95

2019: 15 services

Original Medicare services billed in 2019
New patient visit (60+ min)44$6,625$151
Long return visit (40+ min)44$5,313$97
Removal of polyps or growths of large bowel using an endoscope with mechanical snare16$3,747$234
Biopsy of large bowel using a flexible endoscope23$3,577$156
Biopsy of large bowel using a flexible endoscope23$3,407$148
Removal of polyps or growths of large bowel using an endoscope with mechanical snare15$3,343$223
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,265$181
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes26$3,077$93
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope28$2,694$96
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope23$2,452$107
Diagnostic exam of large bowel using a flexible endoscope14$2,210$158
Diagnostic exam of large bowel using a flexible endoscope12$1,657$138
New patient visit (45+ min)14$1,614$115
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,346$122
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$979$65

2018: 17 services

Original Medicare services billed in 2018
Long return visit (40+ min)72$7,905$88
Biopsy of large bowel using a flexible endoscope52$7,410$142
Biopsy of large bowel using a flexible endoscope41$5,909$144
Removal of polyps or growths of large bowel using an endoscope with mechanical snare21$4,870$232
Removal of polyps or growths of large bowel using an endoscope with mechanical snare22$4,563$207
New patient visit (45+ min)40$4,299$107
Initial hospital care with moderate level of medical decision making at least 75 minutes22$3,961$180
New patient visit (60+ min)27$3,449$128
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope31$3,240$105
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope29$2,363$81
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes23$2,223$89
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes25$2,131$61
Diagnostic exam of large bowel using a flexible endoscope12$2,005$167
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,693$121
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes16$1,668$88
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,177$91
New patient visit (30+ min)12$808$67

2017: 5 services

Original Medicare services billed in 2017
New patient visit (60+ min)22$3,206$146
Long return visit (40+ min)28$2,821$97
Biopsy of large bowel using a flexible endoscope16$1,783$105
New patient visit (45+ min)11$1,153$105
Biopsy of large bowel using a flexible endoscope11$1,014$92

Medicaid work

$8,449 in 2024

Medicaid paid $8,449 for 114 billed services this clinician did in 2024, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)59$7,798
Telehealth transmission, per minute, professional services bill separately55$651
Medicaid work by year
2024114219$8,449
2023114216$6,373
202281417$3,481
2021136419$6,411
202066315$2,772
201928215$5,621
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)58$5,560
Telehealth transmission, per minute, professional services bill separately56$813

2022

Largest Medicaid services in 2022
Long return visit (40+ min)12$1,531
Return visit (30+ min)13$795
Telehealth originating site facility fee13$681
Telehealth transmission, per minute, professional services bill separately43$475

2021

Largest Medicaid services in 2021
Long return visit (40+ min)28$3,384
Telehealth originating site facility fee33$1,623
Infusion, normal saline solution , 1000 cc48$758
TISSUE EXAM BY PATHOLOGIST27$647

2020

Largest Medicaid services in 2020
Upper gastrointestinal endoscopy with biopsy12$1,473
Telehealth originating site facility fee16$819
Telehealth transmission, per minute, professional services bill separately38$480

2019

Largest Medicaid services in 2019
COLONOSCOPY AND BIOPSY13$3,099
Upper gastrointestinal endoscopy with biopsy15$2,522

Drugs they prescribed that Part D paid

$1,488,595

Pharmacies billed $1,488,595 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 307) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.

169 generic and fewer than 11 brand-name prescriptions · $1,488,595 in drug cost · 26 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Gattex17$754,153$44,362
Stelara11$295,663$26,878
Humira(Cf)15$123,167$8,211
Rinvoq16$116,906$7,307
Xifaxan17$55,932$3,290
See all 9 drugs
Every Part D drug this clinician prescribed
Gattex17$754,153$44,362
Stelara11$295,663$26,878
Humira(Cf)15$123,167$8,211
Rinvoq16$116,906$7,307
Xifaxan17$55,932$3,290
Linzess17$15,379$905
Sucralfate21$1,498$71
Omeprazole49$591$12
Pantoprazole35$341$10

Year by year

Part D prescribing by year
20243071030% (0)None$1,488,595
202333998None35%$1,860,203
2022249730% (0)None$1,792,405
2021241730% (0)24%$1,157,309
202031492None15%$178,897
2019150650% (0)21%$28,631
2018265950% (0)None$168,866
20179037None22%$13,459
20162411NoneNone$9,279
201424None0% (0)None$1,074

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 6 drugs

Part D drugs prescribed in 2023
Gattex24$1,101,671$45,903
Stelara17$479,216$28,189
Xifaxan13$30,433$2,341
Sucralfate22$2,664$121
Omeprazole83$1,955$24
Pantoprazole40$937$23

2022: 4 drugs

Part D drugs prescribed in 2022
Gattex37$1,623,164$43,869
Omeprazole64$949$15
Pantoprazole18$811$45
Sucralfate15$710$47

2021: 3 drugs

Part D drugs prescribed in 2021
Gattex26$1,112,337$42,782
Omeprazole81$1,406$17
Famotidine15$282$19

2020: 7 drugs

Part D drugs prescribed in 2020
Budesonide Ec11$4,687$426
Sucralfate18$3,064$170
Omeprazole71$978$14
Ondansetron15$710$47
Pantoprazole15$393$26
Famotidine17$291$17
Gabapentin13$175$13

2019: 2 drugs

Part D drugs prescribed in 2019
Omeprazole37$425$11
Pantoprazole12$81$7

2018: 5 drugs

Part D drugs prescribed in 2018
Budesonide Ec15$7,469$498
Omeprazole67$745$11
Polyethylene Glycol 335016$568$35
Sucralfate14$408$29
Dicyclomine19$105$6

Money from drug and device companies

$29 in 2025

Industry payments by year
202511None$29
202411None$30
202312None$76
202223None$75
202111None$22
202011None$33
201922None$28

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Gilead SciencesNone$29
1 payment
  • Meals · 2025-02-07 · $29
See the published payment
Every published payment
Gilead SciencesMeals · 2025-02-07None$29
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $30

Payments by company in 2024
PfizerVelsipity$30
1 payment
  • Education for Velsipity · 2024-07-09 · $30

2023: $76

Payments by company in 2023
PENTAX of AmericaPentax Medical$76
2 payments
  • Meals for Pentax Medical · 2023-08-29 · $57
  • Meals for Pentax Medical · 2023-06-14 · $19

2022: $75

Payments by company in 2022
Janssen BiotechStelara$52
2 payments
  • Meals for Stelara · 2022-08-31 · $22
  • Meals for Stelara · 2022-07-20 · $30
PENTAX of AmericaVideo Processor$23
1 payment
  • Meals for Video Processor · 2022-06-23 · $23

2021: $22

Payments by company in 2021
AbbVieCreon$22
1 payment
  • Meals for Creon · 2021-12-15 · $22

2020: $33

Payments by company in 2020
Janssen BiotechStelara$33
1 payment
  • Meals for Stelara · 2020-02-12 · $33

2019: $28

Payments by company in 2019
Fresenius Kabi USAPh-Omegaven$14
1 payment
  • Meals for Ph-Omegaven · 2019-10-09 · $14
Janssen BiotechStelara$14
1 payment
  • Meals for Stelara · 2019-09-11 · $14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2022Their institution$82,111
Takeda Pharmaceuticals U.S.A., Inc. · Teduglutide for Treatment of Short Bowel Syndrome in Real World Settings: Center-Based Study in the US and Eu · 2023Their institution$74,316
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2022Their institution$60,620
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2023Their institution$56,866
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2021Their institution$44,002
ABBVIE INC. · M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate To Severe Crohn S Disease (Target Cd) · 2025Their institution$38,823
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021Their institution$37,921
Takeda Pharmaceuticals U.S.A., Inc. · Teduglutide and Nutrient Receptor Ligands, By Reducing Intestinal Permeability, Improve Outcomes in Critical Illness · 2022Their institution$35,935
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2024Their institution$35,798
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2023Their institution$31,715
AbbVie Inc. · Skyrizi · 2020Their institution$30,929
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2024Their institution$23,923
Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2022Their institution$22,184
AbbVie, Inc. · Rinvoq · 2019Their institution$21,537
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 Or M14-433 · 2022Their institution$21,125
AbbVie, Inc. · Skyrizi · 2019Their institution$15,910
ABBVIE INC. · A Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Moderately To Severely Active Crohnx27s Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2022Their institution$14,227
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2025Their institution$12,518
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2025Their institution$12,174
PFIZER INC. · A Phase 2a Multicenter Randomized Doubleblind Placebocontrolled Study With An Open Label Chronic Treatment Period To Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate To Severe Crohns Disease · 2022Their institution$10,374
ABBVIE INC. · M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2025Their institution$10,272
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2023Their institution$10,120
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2021Their institution$9,627
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and An Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis · 2021Their institution$6,518
AbbVie Inc. · Rinvoq · 2020Their institution$6,430
ABBVIE INC. · Study of Targeted Therapies for the Treatment of Adult Participants With Moderate To Severe Crohn S Disease (Target Cd) · 2025Their institution$5,023
Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2023Their institution$3,900
ABBVIE INC. · M16-066 - A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2025Their institution$3,412
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2022Their institution$2,769
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2022Their institution$1,822

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1972892057
Licence
CA A122880California A122880: Current · expires 2028-08-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RG0100X (207RG0100X)
Mailing address
1701 Divisadero St, San Francisco, CA, 94115
NPI first listed
2011-03-29
NPI last updated
2019-03-20

This is when the NPI record was last certified, not a medical board exam.